Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence

Daniel W. Coyne, Stuart M. Sprague, Marc Vervloet, Rosa Ramos, Kamyar Kalantar-Zadeh

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Hyperphosphatemia is a common complication in dialysis-dependent patients with chronic kidney disease. Most dialysis-dependent patients need oral phosphate binder therapy to control serum phosphorus concentrations. Most phosphate binders have a high daily pill burden, which may reduce treatment adherence and impair phosphorus control. Sucroferric oxyhydroxide is a potent iron-based phosphate binder approved for use in dialysis-dependent patients in 2013. A randomized controlled trial of sucroferric oxyhydroxide demonstrated its efficacy for reduction of serum phosphorus with a lower pill burden than sevelamer carbonate. Clinical trials carefully select patients, monitor adherence, and routinely titrate medications to a protocol-defined goal. Consequently, trials may not reflect real-world use of medications. Since its approval, we and others have performed retrospective and prospective analyses of sucroferric oxyhydroxide in real-world clinical practice in > 6400 hemodialysis and approximately 500 peritoneal dialysis patients in the USA and Europe. Consistent with the clinical trial data, real-world observational studies have demonstrated that sucroferric oxyhydroxide can effectively reduce serum phosphorus with a lower daily pill burden than most other phosphate binders. These studies have also shown sucroferric oxyhydroxide provides effective serum phosphorus control in different treatment settings, including as monotherapy in phosphate binder-naïve patients, in patients switching from other phosphate binders, or when used in combination with other phosphate binders. These observational studies indicate a favorable safety and tolerability profile, and minimal, if any, systemic iron absorption. This article reviews the key results from these observational studies of sucroferric oxyhydroxide and evaluates its role in the management of hyperphosphatemia in clinical practice.

Original languageEnglish
Pages (from-to)875-888
Number of pages14
JournalJournal of Nephrology
Issue number3
StatePublished - Apr 2022


  • Chronic kidney disease
  • Hemodialysis
  • Peritoneal dialysis
  • Phosphate binder
  • Phosphorus


Dive into the research topics of 'Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence'. Together they form a unique fingerprint.

Cite this